“The estimated net economic benefits ranged from $640 million to $1.8 billion, with the corresponding net benefits per case averted ranging from $15,780 to $24,391. The per dollar rate of return on the CDC’s investments ranged from $3.88 to $23.85.” Scottt et al (2014).
Scott, R.D.2nd., Sinkowitz-Cochran, R., Wise, M.E., Baggs, J., Goates, S., Solomon, S.L., McDonald, L.C. and Jernigan, J.A. (2014) CDC Central-Line Bloodstream Infection Prevention Efforts Produced Net Benefits Of At Least $640 Million During 1990-2008. Health Affairs. 33(6), p.1040-7.
Net benefits of central-line associated bloodstream infection prevention efforts http://ctt.ec/7s2eU+ @ivteam #ivteam
The prevention of central line-associated bloodstream infections in patients in hospital critical care units has been a target of efforts by the Centers for Disease Control and Prevention (CDC) since the 1960s. We developed a historical economic model to measure the net economic benefits of preventing these infections in Medicare and Medicaid patients in critical care units for the period 1990-2008-a time when reductions attributable to federal investment resulted primarily from CDC efforts-using the cost perspective of the federal government as a third-party payer. The estimated net economic benefits ranged from $640 million to $1.8 billion, with the corresponding net benefits per case averted ranging from $15,780 to $24,391. The per dollar rate of return on the CDC’s investments ranged from $3.88 to $23.85. These findings suggest that investments in CDC programs targeting other health care-associated infections also have the potential to produce savings by lowering Medicare and Medicaid reimbursements.
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).
- Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
- CancerUK IV chemotherapy information.